BioArdis

Executive Summary

BioArdis is a private, pre-clinical biotechnology company headquartered in San Diego, CA, founded in 2021. The company is developing a diversified pipeline of oncology and immuno-oncology therapeutics, combining small molecule drug candidates with a novel CAR-T platform engineered to target solid tumors. BioArdis leverages a proprietary high-throughput screening engine to accelerate discovery and development. While the company is still in the early stages, its dual approach addresses key challenges in cancer therapy, including the difficulty of targeting solid tumors with CAR-T. The pre-clinical stage means that significant milestones, such as IND filings and initial clinical data, are required to validate the technology. The company's progress will depend on successful preclinical studies and securing additional funding or partnerships.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead Small Molecule Candidate30% success
• Q1 2027Preclinical Proof-of-Concept Data for CAR-T Platform40% success
• Q4 2026Series A Funding Round50% success